Professor Paul Kalra

  • Honorary Clinical Senior Lecturer (School of Health & Wellbeing)

Portsmouth Hospitals University NHS Trust, Queen Alexandra Hospital, Southwick Hill Rd, Cosham, PO6 3LY

Import to contacts

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018
Number of items: 23.

2024

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Graham, F. J., Guha, K., Cleland, J. G. and Kalra, P. R. (2024) Treating iron deficiency in patients with heart failure: what, why, when, how, where and who. Heart, (doi: 10.1136/heartjnl-2022-322030) (PMID:39160066) (Early Online Publication)

Cleland, J. et al. (2024) The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Journal of the American College of Cardiology, (Accepted for Publication)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Packer, M., Anker, S. D., Butler, J., Cleland, J. G.F. , Kalra, P. R., Mentz, R. J., Ponikowski, P. and Talha, K. M. (2024) Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. European Journal of Heart Failure, 26(6), pp. 1298-1312. 38727791. (doi: 10.1002/ejhf.3237)

Ray, R. et al. (2024) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, 30(5), pp. 682-690. (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (PMCID:PMC11096866)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

2023

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Austin, R. C., Schoonhoven, L., Richardson, A., Kalra, P. R. and May, C. R. (2023) Qualitative interviews results from heart failure survey respondents on the interaction between symptoms and burden of self-care work. Journal of Clinical Nursing, 32(15-16), pp. 4649-4662. (doi: 10.1111/jocn.16484) (PMID:35945903)

Ford, I. and Kalra, P. R. (2023) Unanswered questions from the IRONMAN trial - authors' reply. Lancet, 401(10387), pp. 1495-1496. (doi: 10.1016/S0140-6736(23)00448-8) (PMID:37149301)

Graham, F. J., Pellicori, P. , Kalra, P. R., Ford, I. , Bruzzese, D. and Cleland, J. G.F. (2023) Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. European Journal of Heart Failure, 25(4), pp. 528-537. (doi: 10.1002/ejhf.2810) (PMID:36823953)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Austin, R. C., Schoonhoven, L., Koutra, V., Richardson, A., Kalra, P. R. and May, C. R. (2022) SYMptoms in chronic heart failure imPACT on burden of treatment (SYMPACT): a cross‐sectional survey. ESC Heart Failure, 9(4), pp. 2279-2290. (doi: 10.1002/ehf2.13904) (PMID:35451208) (PMCID:PMC9288776)

2021

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Austin, R. C., Schoonhoven, L., Clancy, M., Richardson, A., Kalra, P. R. and May, C. R. (2021) Do chronic heart failure symptoms interact with burden of treatment? Qualitative literature systematic review. BMJ Open, 11(7), e047060. (doi: 10.1136/bmjopen-2020-047060) (PMID:34330858) (PMCID:PMC8327846)

2020

Austin, R. C., Schoonhoven, L., Richardson, A., Kalra, P. R. and May, C. R. (2020) How do SYMPtoms and management tasks in chronic heart failure imPACT a person's life (SYMPACT)? Protocol for a mixed-methods study. ESC Heart Failure, 7(6), pp. 4472-4477. (doi: 10.1002/ehf2.13010) (PMID:32940966) (PMCID:PMC7754908)

Sorbets, E. et al. (2020) Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 41(3), pp. 347-356. (doi: 10.1093/eurheartj/ehz660) (PMID:31504434) (PMCID:PMC6964227)

2019

Vidal-Petiot, E. et al. (2019) Chronic kidney disease has a graded association with death and cardiovascular outcomes in stable coronary artery disease: an analysis of 21,911 patients from the CLARIFY registry. Journal of Clinical Medicine, 9(1), 4. (doi: 10.3390/jcm9010004)

Clark, A. L., Kalra, P. R., Petrie, M. C. , Mark, P. B. , Tomlinson, L. A. and Tomson, C. R.V. (2019) Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 105(12), pp. 904-910. (doi: 10.1136/heartjnl-2018-314158) (PMID:31118203) (PMCID:PMC6582720)

2018

Kalra, P. R., Greenlaw, N. , Ford, I. , Steg, P. G. and Fox, K. M. (2018) The reply. American Journal of Medicine, 131(3), e129. (doi: 10.1016/j.amjmed.2017.09.019) (PMID:29454433)

This list was generated on Thu Dec 5 11:50:22 2024 GMT.
Jump to: Articles
Number of items: 23.

Articles

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Graham, F. J., Guha, K., Cleland, J. G. and Kalra, P. R. (2024) Treating iron deficiency in patients with heart failure: what, why, when, how, where and who. Heart, (doi: 10.1136/heartjnl-2022-322030) (PMID:39160066) (Early Online Publication)

Cleland, J. et al. (2024) The IRONMAN trial of intravenous iron for heart failure. Adjudication of hospitalizations and deaths. Journal of the American College of Cardiology, (Accepted for Publication)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Packer, M., Anker, S. D., Butler, J., Cleland, J. G.F. , Kalra, P. R., Mentz, R. J., Ponikowski, P. and Talha, K. M. (2024) Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. European Journal of Heart Failure, 26(6), pp. 1298-1312. 38727791. (doi: 10.1002/ejhf.3237)

Ray, R. et al. (2024) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, 30(5), pp. 682-690. (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (PMCID:PMC11096866)

Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Austin, R. C., Schoonhoven, L., Richardson, A., Kalra, P. R. and May, C. R. (2023) Qualitative interviews results from heart failure survey respondents on the interaction between symptoms and burden of self-care work. Journal of Clinical Nursing, 32(15-16), pp. 4649-4662. (doi: 10.1111/jocn.16484) (PMID:35945903)

Ford, I. and Kalra, P. R. (2023) Unanswered questions from the IRONMAN trial - authors' reply. Lancet, 401(10387), pp. 1495-1496. (doi: 10.1016/S0140-6736(23)00448-8) (PMID:37149301)

Graham, F. J., Pellicori, P. , Kalra, P. R., Ford, I. , Bruzzese, D. and Cleland, J. G.F. (2023) Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. European Journal of Heart Failure, 25(4), pp. 528-537. (doi: 10.1002/ejhf.2810) (PMID:36823953)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Austin, R. C., Schoonhoven, L., Koutra, V., Richardson, A., Kalra, P. R. and May, C. R. (2022) SYMptoms in chronic heart failure imPACT on burden of treatment (SYMPACT): a cross‐sectional survey. ESC Heart Failure, 9(4), pp. 2279-2290. (doi: 10.1002/ehf2.13904) (PMID:35451208) (PMCID:PMC9288776)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Austin, R. C., Schoonhoven, L., Clancy, M., Richardson, A., Kalra, P. R. and May, C. R. (2021) Do chronic heart failure symptoms interact with burden of treatment? Qualitative literature systematic review. BMJ Open, 11(7), e047060. (doi: 10.1136/bmjopen-2020-047060) (PMID:34330858) (PMCID:PMC8327846)

Austin, R. C., Schoonhoven, L., Richardson, A., Kalra, P. R. and May, C. R. (2020) How do SYMPtoms and management tasks in chronic heart failure imPACT a person's life (SYMPACT)? Protocol for a mixed-methods study. ESC Heart Failure, 7(6), pp. 4472-4477. (doi: 10.1002/ehf2.13010) (PMID:32940966) (PMCID:PMC7754908)

Sorbets, E. et al. (2020) Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 41(3), pp. 347-356. (doi: 10.1093/eurheartj/ehz660) (PMID:31504434) (PMCID:PMC6964227)

Vidal-Petiot, E. et al. (2019) Chronic kidney disease has a graded association with death and cardiovascular outcomes in stable coronary artery disease: an analysis of 21,911 patients from the CLARIFY registry. Journal of Clinical Medicine, 9(1), 4. (doi: 10.3390/jcm9010004)

Clark, A. L., Kalra, P. R., Petrie, M. C. , Mark, P. B. , Tomlinson, L. A. and Tomson, C. R.V. (2019) Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 105(12), pp. 904-910. (doi: 10.1136/heartjnl-2018-314158) (PMID:31118203) (PMCID:PMC6582720)

Kalra, P. R., Greenlaw, N. , Ford, I. , Steg, P. G. and Fox, K. M. (2018) The reply. American Journal of Medicine, 131(3), e129. (doi: 10.1016/j.amjmed.2017.09.019) (PMID:29454433)

This list was generated on Thu Dec 5 11:50:22 2024 GMT.